Japan Committee Recommends 6 Drugs Including Pfizer’s Bosulif
This article was originally published in PharmAsia News
Executive Summary
The Second Committee on Drugs of Japan’s MHLW recommended for approval six drugs on Sept. 5 including Pfizer‘s new molecular-targeted therapy Bosulif (bosutinib) for chronic myeloid leukemia.